249 related articles for article (PubMed ID: 7543270)
1. Antiviral action of oligodeoxyguanylic acids against human immunodeficiency virus type 1.
Fujihashi T; Sakata T; Kaji A; Kaji H
AIDS Res Hum Retroviruses; 1995 Apr; 11(4):461-71. PubMed ID: 7543270
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of HIV infection by baicalin--a flavonoid compound purified from Chinese herbal medicine.
Li BQ; Fu T; Yan YD; Baylor NW; Ruscetti FW; Kung HF
Cell Mol Biol Res; 1993; 39(2):119-24. PubMed ID: 7693133
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of human immunodeficiency virus activity by phosphorodithioate oligodeoxycytidine.
Marshall WS; Beaton G; Stein CA; Matsukura M; Caruthers MH
Proc Natl Acad Sci U S A; 1992 Jul; 89(14):6265-9. PubMed ID: 1378623
[TBL] [Abstract][Full Text] [Related]
4. Effects of tubeimoside-1 on HIV core protein p24 and cytopathogenesis in vitro.
Yu LJ; Ma RD; Jiang SB
Zhongguo Yao Li Xue Bao; 1994 Mar; 15(2):103-6. PubMed ID: 8010099
[TBL] [Abstract][Full Text] [Related]
5. Diarylsulfones, a new chemical class of nonnucleoside antiviral inhibitors of human immunodeficiency virus type 1 reverse transcriptase.
McMahon JB; Gulakowski RJ; Weislow OS; Schultz RJ; Narayanan VL; Clanton DJ; Pedemonte R; Wassmundt FW; Buckheit RW; Decker WD
Antimicrob Agents Chemother; 1993 Apr; 37(4):754-60. PubMed ID: 7684215
[TBL] [Abstract][Full Text] [Related]
6. Short, terminally phosphorylated oligoriboguanylic acids effectively inhibit cytopathicity caused by human immunodeficiency virus.
Fujihashi T; Sakata T; Kaji A; Kaji H
Biochem Biophys Res Commun; 1994 Sep; 203(2):1244-50. PubMed ID: 7916572
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of HIV-1 replication in H9 cells by nystatin-A compared with other antiviral agents.
Selvam MP; Blay RA; Geyer S; Buck SM; Pollock L; Mayner RE; Epstein JS
AIDS Res Hum Retroviruses; 1993 May; 9(5):475-81. PubMed ID: 7686387
[TBL] [Abstract][Full Text] [Related]
8. Mode of action of SDZ NIM 811, a nonimmunosuppressive cyclosporin A analog with activity against human immunodeficiency virus type 1 (HIV-1): interference with early and late events in HIV-1 replication.
Steinkasserer A; Harrison R; Billich A; Hammerschmid F; Werner G; Wolff B; Peichl P; Palfi G; Schnitzel W; Mlynar E
J Virol; 1995 Feb; 69(2):814-24. PubMed ID: 7815548
[TBL] [Abstract][Full Text] [Related]
9. Potent and specific inhibition of HIV envelope-mediated cell fusion and virus binding by G quartet-forming oligonucleotide (ISIS 5320).
Buckheit RW; Roberson JL; Lackman-Smith C; Wyatt JR; Vickers TA; Ecker DJ
AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1497-506. PubMed ID: 7888204
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of HIV-1 in CEM cells by a potent TAR decoy.
Lee SW; Gallardo HF; Gaspar O; Smith C; Gilboa E
Gene Ther; 1995 Aug; 2(6):377-84. PubMed ID: 7584112
[TBL] [Abstract][Full Text] [Related]
11. In vitro assessment of compounds for anti-HIV activity.
Patience C; Moore J; Boyd M
Mol Biotechnol; 1994 Feb; 1(1):49-58. PubMed ID: 7532100
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by daphnodorins.
Yusa K; Oh-hara T; Tsukahara S; Baba K; Taniguchi M; Kozawa M; Takeuchi S; Hara H; Tsuruo T
Antiviral Res; 1994 Sep; 25(1):57-66. PubMed ID: 7529015
[TBL] [Abstract][Full Text] [Related]
13. Effects of serotonin and melanin on in vitro HIV-1 infection.
Sidibe S; Saal F; Rhodes-Feuillette A; Lagaye S; Pelicano L; Canivet M; Peries J; Dianoux L
J Biol Regul Homeost Agents; 1996; 10(1):19-24. PubMed ID: 9049777
[TBL] [Abstract][Full Text] [Related]
14. A monoclonal antibody to the gp120-CD4 complex has differential effect on HIV-induced syncytium formation and viral infectivity.
Konopka K; Pretzer E; Celada F; Düzgüneş N
J Gen Virol; 1995 Mar; 76 ( Pt 3)():669-79. PubMed ID: 7897355
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of human immunodeficiency virus type 1 replication by 7-methyl-6,8-bis(methylthio)pyrrolo[1,2-a]pyrazine, an in vivo metabolite of oltipraz.
Prochaska HJ; Bornmann WG; Baron P; Polsky B
Mol Pharmacol; 1995 Jul; 48(1):15-20. PubMed ID: 7542738
[TBL] [Abstract][Full Text] [Related]
16. Newly designed six-membered azasugar nucleotide-containing phosphorothioate oligonucleotides as potent human immunodeficiency virus type 1 inhibitors.
Lee DS; Jung KE; Yoon CH; Lim H; Bae YS
Antimicrob Agents Chemother; 2005 Oct; 49(10):4110-20. PubMed ID: 16189087
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of anti-human immunodeficiency virus action of polyoxometalates, a class of broad-spectrum antiviral agents.
Yamamoto N; Schols D; De Clercq E; Debyser Z; Pauwels R; Balzarini J; Nakashima H; Baba M; Hosoya M; Snoeck R
Mol Pharmacol; 1992 Dec; 42(6):1109-17. PubMed ID: 1282664
[TBL] [Abstract][Full Text] [Related]
18. Phosphorothioate analogues of oligodeoxyribonucleotide: synthesis and activity as inhibitors of replication of human immunodeficiency virus.
Kim SG; Suzuki Y; Nakashima H; Yamamoto N; Takaku H
Biochem Biophys Res Commun; 1991 Sep; 179(3):1614-9. PubMed ID: 1930201
[TBL] [Abstract][Full Text] [Related]
19. Novel, negatively charged, human serum albumins display potent and selective in vitro anti-human immunodeficiency virus type 1 activity.
Jansen RW; Schols D; Pauwels R; De Clercq E; Meijer DK
Mol Pharmacol; 1993 Nov; 44(5):1003-7. PubMed ID: 7902528
[TBL] [Abstract][Full Text] [Related]
20. The proteinase inhibitor pepstatin A inhibits formation of reverse transcriptase in H9 cells infected with human immunodeficiency virus 1.
Grinde B; Hungnes O; Tjøtta E
AIDS Res Hum Retroviruses; 1989 Jun; 5(3):269-74. PubMed ID: 2471542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
